Trademark: 79295795
Word
ITM MEDICAL ISOTOPES
Status Date
Tuesday, June 15, 2021
Registration Number
6383043
Registration Date
Tuesday, June 15, 2021
Filing Date
Tuesday, July 28, 2020
Published for Opposition
Tuesday, March 30, 2021
5 Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, in particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; theranostics in the field of precision oncology; radiopharmaceutical products, namely, lutetium-containing precursors for imaging and detection for diagnosing and monitoring cancer; solutions for radioactive labelling being medical diagnostic preparations; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceuticals containing radioisotopes, e.g. lutetium-177, actinium-225, yttrium-90 for treatment and radioisotopes such as gallium-68 or fluorine-18 for diagnosis of tumours; target radiopharmaceuticals containing a target molecule, e.g. peptide or antibody, depending on the indication and a medical radioactive isotope for diagnosis purposes; radiopharmaceuticals containing gallium and its complexes, gallium-68 DOTATOC for treatment of cancer; 177Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]; radiopharmaceuticals for use in the therapy of GEP-NET, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer; radiopharmaceuticals containing radioisotopes with short half-lives, such as gallium-68 or fluorine-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as PET [positron emission tomography] or SPECT [single photon emission tomography], for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular lutetium-177, actinium-225 or yttrium-90 for the treatment of tumour diseases
10 Medical instruments, apparatus and containers for the application of radiopharmaceutical and radiodiagnostic preparations; controlling, regulating and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnosis with a radiotherapeutic or radiodiagnostic substance; radionuclide generators being medical instruments for radiopharmaceutical purposes
42 Conducting clinical trials for others at all stages and in various indications, particularly in oncology; conducting phase III clinical trials for others with target radiopharmaceutical 177Lu-Edotreotide in patients with neuroendocrine tumours of gastroenteric or pancreatic origin [GEP-NET]
44 Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapies, including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology
"MEDICAL ISOTOPES"
The mark consists of "ITM MEDICAL ISOTOPES" in stylized form with two circles emanating from the left corner of the "I" in "ITM" at a diagonal.
Nov 26, 2021
Change Of Name/Address Rec'd From Ib
Nov 15, 2021
Final Decision Transaction Processed By Ib
Oct 21, 2021
New Representative At Ib Received
Sep 30, 2021
Generic Madrid Transaction Sent To Ib
Sep 30, 2021
Generic Madrid Transaction Created
Sep 15, 2021
Final Disposition Notice Created, To Be Sent To Ib
Jun 15, 2021
Registered-Principal Register
Apr 5, 2021
Notification Processed By Ib
Mar 30, 2021
Official Gazette Publication Confirmation E-Mailed
Mar 30, 2021
Published For Opposition
Mar 15, 2021
Notification Of Possible Opposition Sent To Ib
Mar 10, 2021
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Mar 10, 2021
Notification Of Notice Of Publication E-Mailed
Feb 23, 2021
Approved For Pub - Principal Register
Feb 23, 2021
Examiner's Amendment Entered
Feb 23, 2021
Notification Of Examiners Amendment E-Mailed
Feb 23, 2021
Examiners Amendment E-Mailed
Feb 23, 2021
Examiners Amendment -Written
Feb 12, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Feb 12, 2021
Teas Change Of Correspondence Received
Feb 12, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 12, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Feb 12, 2021
Teas Change Of Owner Address Received
Feb 14, 2021
Teas/Email Correspondence Entered
Feb 12, 2021
Correspondence Received In Law Office
Feb 12, 2021
Teas Response To Office Action Received
Dec 27, 2020
Refusal Processed By Ib
Dec 8, 2020
Non-Final Action Mailed - Refusal Sent To Ib
Dec 8, 2020
Refusal Processed By Mpu
Nov 20, 2020
Non-Final Action (Ib Refusal) Prepared For Review
Nov 19, 2020
Non-Final Action Written
Nov 16, 2020
Assigned To Examiner
Oct 23, 2020
Application Filing Receipt Mailed
Oct 19, 2020
New Application Office Supplied Data Entered In Tram
Oct 15, 2020
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
